drug
fremanezumab
Marketedupdated 4mo agoby Teva Pharmaceuticals USA Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying fremanezumab
- phase3A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
- phase4Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
- phase4Fremanezumab, Migraine and Sleep
- phase3A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age
- phase3A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
- —Fremanezumab Compassionate Use Program for Pediatric Patients
- phase3A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
- —Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity
News(5)
- New guidelines on migraine prevention reflect increasing options for patients“There has been a wealth of new treatment available” for migraine prevention, said a co-author of new guidelines released Monday.stat · 18d ago
- Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trialsSlate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead c…fiercebiotech · 1mo ago
- A new Westlake-backed biotech takes aim at migrainesVedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.biopharma_dive · 3mo ago
- Study data convince Lundbeck to push new migraine drug forwardA possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.biopharma_dive · 3mo ago
- Teva nabs experimental Tourette drug in $700M Emalex buyoutA Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.biopharma_dive · 4mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that